Current Report Filing (8-k)
February 09 2022 - 7:32AM
Edgar (US Regulatory)
0001823857
false
0001823857
2022-01-12
2022-01-12
0001823857
VHAQ:UnitsMember
2022-01-12
2022-01-12
0001823857
us-gaap:CommonStockMember
2022-01-12
2022-01-12
0001823857
VHAQ:WarrantsMember
2022-01-12
2022-01-12
0001823857
us-gaap:RightsMember
2022-01-12
2022-01-12
iso4217:USD
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January
12, 2022
Viveon Health Acquisition Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-39827
|
|
85-2788202
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
c/o Gibson, Deal & Fletcher, PC
Spalding Exchange
3953 Holcomb Bridge Rd., Suite200
Norcross,
GA 30092
(Address of Principal Executive Offices and Zip
Code)
Registrant’s telephone number, including
area code: (404) 861-5393
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☒
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
|
|
|
|
Units
|
|
VHAQU
|
|
NYSE American, LLC
|
|
|
|
|
|
Common Stock
|
|
VHAQ
|
|
NYSE American, LLC
|
|
|
|
|
|
Warrants
|
|
VHAQW
|
|
NYSE American, LLC
|
|
|
|
|
|
Rights
|
|
VHAQR
|
|
NYSE American, LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
As previously announced, on January 12, 2022, Viveon
Health Acquisition Corp., a Delaware corporation (“Viveon”), entered into a Merger Agreement (the “Merger Agreement”)
by and among Viveon, VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Viveon (“Merger Sub”),
and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Merger Agreement, a business combination
between Viveon and Suneva will be effected through the merger of Merger Sub with and into Suneva, with Suneva surviving the merger as
a wholly owned subsidiary of Viveon (the “Merger”). The board of directors of Viveon has (i) approved and declared advisable
the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger
Agreement and related transactions by the stockholders of Viveon.
On January 12, 2022, Pat Altavilla, President and
Chief Executive Officer of Suneva was interviewed by: (i) Nicole Petallides for live streaming and subsequent website posting on the TD
Ameritrade Network, and (ii) Michelle F. Davis of Bloomberg for subsequent publication.
On February 8, 2022, Suneva issued a press release
announcing its distribution of more than 1 million syringes of Suneva’s Bellafill® product.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 8, 2022
Viveon Health Acquisition Corp.
|
|
|
|
|
By:
|
/s/ Jagi Gill
|
|
Name:
|
Jagi Gill
|
|
Title:
|
Chief Executive Officer
|
|
2
Viveon Health Acquisition (AMEX:VHAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viveon Health Acquisition (AMEX:VHAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024